Vol. 6 No. 1 (2026)
Reimbursement Reviews

Brentuximab Vedotin

decorative image of the issue cover

Published January 6, 2026

Key Messages

  • Reimbursement reviews of drugs later in the life cycle include a comprehensive assessment of clinical value, unmet clinical need, distinct social and ethical considerations, economic considerations, and impacts on the health systems.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial drug plans and cancer agencies.
  • This review assesses BrECADD; the key drug in the combination is brentuximab vedotin (IV).
  • Indication under consideration for reimbursement: Treatment of adult patients with newly diagnosed, advanced-stage, classical Hodgkin lymphoma.